EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.454
https://www.valueinhealthjournal.com/article/S1098-3015(23)00554-5/fulltext
Title :
EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00554-5&doi=10.1016/j.jval.2023.03.454
First page :
Section Title :
Open access? :
No
Section Order :
11836